Little Rock, AR (13 May 2019) – InterveXion Therapeutics, a private clinical-stage biopharmaceutical company focused on developing immunotherapies for substance abuse disorders, today announced an expansion to its Executive Leadership Team that strengthens the team and further prepares the company for future growth.
Misty Stevens, Ph.D., M.B.A. has been appointed Chief Operating Officer of InterveXion, and Ralph Henry, Ph.D. has been appointed Executive Vice President, Corporate Development and Biopharmaceutics.
Dr. Stevens has served as Operations Director for InterveXion for the past 12 years, where she has overseen all scientific operations and project management activities for the company. Furthermore, she has also led grant writing and administration, business plan and budget development, and patent filings. Prior to joining InterveXion, Dr. Stevens performed post-doctoral research at Harvard Medical School. Dr. Stevens earned her Ph.D. in Biology and her M.B.A in Management from the University of Arkansas.
Dr. Henry is a Co-Founder of InterveXion, and most recently served as VP of Biopharmaceutics for the company, where he led manufacturing and testing of InterveXion’s product candidates. Dr. Henry also serves as VP of Life Science and Medical Technology for VIC Technology Venture Development. Prior to his current roles, Dr. Henry was Distinguished Professor, Biological Sciences at the University of Arkansas. Dr. Henry earned his Ph.D. in Membrane Protein Assembly from Kansas State University.
“We are delighted to announce these key promotions for Drs. Stevens and Henry,” said W. Brooks Gentry, M.D., InterveXion’s Chief Medical Officer. “With our lead antibody in Phase 2 clinical testing, and our most advanced vaccine in late preclinical development, Drs. Stevens and Henry will play an even more critical role in developing our product candidates and engaging with external partners. We look forward to continuing to work together to seek solutions for patients suffering from substance use disorders”.
InterveXion is the leading biopharmaceutical company developing immunotherapies for patients with substance abuse disorders. InterveXion’s lead product, IXT-m200, is a monoclonal antibody against methamphetamine which has received US FDA Fast Track Designation and which is currently undergoing Phase 2 proof-of-concept testing in the STAMPOUT study (NCT0333866). For more information, visit: https://www.intervexion.com.